发布求助
文献互助 智能选刊 最新文献

Melanoma Management最新文献

筛选
英文 中文
COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE. 对抗nras突变黑色素瘤:从实验室到床边。
IF 3.6
Melanoma Management Pub Date : 2017-12-01 Epub Date: 2017-11-21 DOI: 10.2217/mmt-2017-0023
Ileabett M Echevarría-Vargas, Jessie Villanueva
{"title":"COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE.","authors":"Ileabett M Echevarría-Vargas, Jessie Villanueva","doi":"10.2217/mmt-2017-0023","DOIUrl":"https://doi.org/10.2217/mmt-2017-0023","url":null,"abstract":"“ Oncogenic NRAS plays a critical role in melanoma initiation and maintenance; however, to date there are no effective ways to directly block the activity of mutant NRAS. ” NRAS is the second most common oncogenic driver in melanoma, mutated predominantly at codon 61 in almost 30% of all melanomas [1] . Tumors bearing NRAS mutations are highly aggressive and are associated with shorter patient survival [2] . Despite the prevalence of NRAS mutations and the severity of the resulting disease, treatment for NRAS mutant melanoma has lagged far behind BRAF-mutant tumors. Here, we summarize the status of the most promising strategies, highlighting the successes and the gaps that remain to be filled. GTP guanine-nucleotide exchange mutant form of to GAPs, leading to NRAS activation and persistent signaling that triggers and","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"4 4","pages":"183-186"},"PeriodicalIF":3.6,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36118032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma. 免疫检查点抑制剂治疗晚期粘膜黑色素瘤。
IF 3.6
Melanoma Management Pub Date : 2017-09-01 Epub Date: 2017-10-04 DOI: 10.2217/mmt-2017-0014
James C Kuo
{"title":"Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma.","authors":"James C Kuo","doi":"10.2217/mmt-2017-0014","DOIUrl":"https://doi.org/10.2217/mmt-2017-0014","url":null,"abstract":"<p><p>Immunotherapy with immune checkpoint inhibitors is the standard of care in the treatment of advanced melanoma. Treatment outcome of these agents is less defined for the rare subtype of mucosal melanoma. In this single-institutional case series, the objective response rate was low at 11.8%, but durable response was seen, including a complete response to first-line ipilimumab and to second-line pembrolizumab. Survival remained poor; at the median follow-up of 10.1 months, the median progression-free survival and overall survival were 3.1 and 8.8 months respectively. Nevertheless, among the few responders, survival of up to 56+ months was observed. Other treatment strategies need to be explored to improve treatment outcome for this rare subtype.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"4 3","pages":"161-167"},"PeriodicalIF":3.6,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36470685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide? 抗pd -1单药治疗与抗pd -1 +抗ctla4治疗晚期黑色素瘤:我们如何决定?
IF 3.6
Melanoma Management Pub Date : 2017-09-01 Epub Date: 2017-08-02 DOI: 10.2217/mmt-2017-0016
Lewis Au, Aine O'Reilly, James Larkin
{"title":"Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?","authors":"Lewis Au,&nbsp;Aine O'Reilly,&nbsp;James Larkin","doi":"10.2217/mmt-2017-0016","DOIUrl":"https://doi.org/10.2217/mmt-2017-0016","url":null,"abstract":"","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"4 3","pages":"151-155"},"PeriodicalIF":3.6,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36468077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project. 全基因组测序鉴定肿瘤病因和临床可操作的基因组畸变的优势:来自澳大利亚黑色素瘤基因组计划的经验教训。
IF 3.6
Melanoma Management Pub Date : 2017-09-01 Epub Date: 2017-07-26 DOI: 10.2217/mmt-2017-0008
James S Wilmott, Nicholas K Hayward, Graham J Mann, Richard A Scolyer
{"title":"Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project.","authors":"James S Wilmott,&nbsp;Nicholas K Hayward,&nbsp;Graham J Mann,&nbsp;Richard A Scolyer","doi":"10.2217/mmt-2017-0008","DOIUrl":"https://doi.org/10.2217/mmt-2017-0008","url":null,"abstract":"","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"4 3","pages":"147-149"},"PeriodicalIF":3.6,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36468076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Can we improve melanoma detection methods? 我们能改进黑色素瘤的检测方法吗?
IF 3.6
Melanoma Management Pub Date : 2017-09-01 Epub Date: 2017-07-26 DOI: 10.2217/mmt-2017-0009
Riccardo Pampena, Caterina Longo
{"title":"Can we improve melanoma detection methods?","authors":"Riccardo Pampena,&nbsp;Caterina Longo","doi":"10.2217/mmt-2017-0009","DOIUrl":"https://doi.org/10.2217/mmt-2017-0009","url":null,"abstract":"","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"4 3","pages":"139-142"},"PeriodicalIF":3.6,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36468073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Survivor and patient advocate: an interview with T.J. Sharpe. 幸存者和病人的倡导者:对T.J.夏普的采访。
IF 3.6
Melanoma Management Pub Date : 2017-09-01 Epub Date: 2017-07-31 DOI: 10.2217/mmt-2017-0012
Thomas J Sharpe
{"title":"Survivor and patient advocate: an interview with T.J. Sharpe.","authors":"Thomas J Sharpe","doi":"10.2217/mmt-2017-0012","DOIUrl":"https://doi.org/10.2217/mmt-2017-0012","url":null,"abstract":"<p><p><b>T.J. Sharpe speaks to Sebastian Dennis-Beron, Commissioning Editor:</b> T.J. Sharpe is a stage IV melanoma patient who shares his journey through cancer in the Patient #1 Blog [1]. He was diagnosed in August 2012 with melanoma tumors in multiple organs; since then, he has undergone six surgeries and four immunotherapy treatments over two different clinical trials. The initial failures and subsequent significantly positive response have been chronicled in his blog posts since January 2013. His story is about life with a serious illness, and the mental and emotional hurdles a patient must clear. He writes how a cancer patient's challenges mirror those many face, and portrays life through the optimistic prism of a patient who is on the long, winding road toward overcoming melanoma's long odds and deadly consequences. He also shares the latest melanoma and oncology research breakthroughs and advocacy events, and initiatives to help others avoid, detect or educate themselves on cancer. As part of his advocacy, he attends cancer and melanoma conferences, reporting on the latest medical breakthroughs through his blog to other cancer patients. He also partners with advocacy organizations, clinical trial groups and the pharmaceutical industry to bring awareness to cancer research and developments. His efforts have been recognized by several organizations, including the Melanoma Research Foundation, Melanoma International Foundation, Patient Power, Forbes, Merck, GlaxoSmithKline, the Drug Information Association and the Milken Institute's FasterCures. In December 2014, he was able to share his story on Capitol Hill in a special session promoting immunotherapy research to lawmakers. A South Jersey native, T.J. lives in Fort Lauderdale with his wife Jennifer and two young children, Josie and Tommy. He is active in health and wellness initiatives, including melanoma/cancer awareness runs and bike rides, and an avid yoga participant. He also serves on the Board of Directors of A Prom to Remember, a 501</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"4 3","pages":"157-160"},"PeriodicalIF":3.6,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36470684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. ipilimumab在抗pd -1治疗进展的黑色素瘤患者中的应用
IF 3.6
Melanoma Management Pub Date : 2017-09-01 Epub Date: 2017-07-26 DOI: 10.2217/mmt-2017-0010
Cesar E Ochoa, Richard W Joseph
{"title":"Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy.","authors":"Cesar E Ochoa,&nbsp;Richard W Joseph","doi":"10.2217/mmt-2017-0010","DOIUrl":"https://doi.org/10.2217/mmt-2017-0010","url":null,"abstract":"survival","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"4 3","pages":"143-145"},"PeriodicalIF":3.6,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36468075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Are PD-1 antibodies safe for use in metastatic uveal melanoma? PD-1抗体用于转移性葡萄膜黑色素瘤安全吗?
IF 3.6
Melanoma Management Pub Date : 2017-05-01 Epub Date: 2017-05-10 DOI: 10.2217/mmt-2017-0007
Katy K Tsai, Alain P Algazi
{"title":"Are PD-1 antibodies safe for use in metastatic uveal melanoma?","authors":"Katy K Tsai,&nbsp;Alain P Algazi","doi":"10.2217/mmt-2017-0007","DOIUrl":"https://doi.org/10.2217/mmt-2017-0007","url":null,"abstract":"prospective data support similar findings: 0 of 53 patients had objective response, 2-year OS rate was 7% and safety data showed 16 patients (30%) with grade 1–2 AEs and 19 patients (36%) with grade 3–4 AEs [25] . Grade 3–4 AEs were diarrhea, colitis and transaminitis. There was one possible treatment-related death in the setting of pancytopenia with subsequent cerebral hemorrhage and respiratory insufficiency. An abstract from a second Phase II study of ipilimumab 10 mg/kg (EudraCT 2010–024415–4) in 32 patients reported 15 patients (47%) with grade 3–4 AEs (abdominal pain, hypophysitis, emesis, diarrhea, asthenia, proctalgia, bone pain, urinary tract infection, hepatotoxicity, multi-organ failure, altered state of consciousness and vascular compression) [26] . Responses were similarly modest, with one partial response and six patients with stable disease at a median follow-up of 5.5 months.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":" ","pages":"79-82"},"PeriodicalIF":3.6,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36468066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Melanoma treatment guided by a panel of microRNA biomarkers. 由一组microRNA生物标志物指导的黑色素瘤治疗。
IF 3.6
Melanoma Management Pub Date : 2017-05-01 Epub Date: 2017-05-10 DOI: 10.2217/mmt-2017-0006
Mitchell S Stark
{"title":"Melanoma treatment guided by a panel of microRNA biomarkers.","authors":"Mitchell S Stark","doi":"10.2217/mmt-2017-0006","DOIUrl":"https://doi.org/10.2217/mmt-2017-0006","url":null,"abstract":"","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":" ","pages":"75-77"},"PeriodicalIF":3.6,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36468065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
When to consider alternatives to front-line immune therapies in metastatic melanoma. 在转移性黑色素瘤中，何时考虑替代一线免疫疗法。
IF 3.6
Melanoma Management Pub Date : 2017-05-01 DOI: 10.2217/mmt-2017-0005
Daniel Y Wang, Douglas B Johnson
{"title":"When to consider alternatives to front-line immune therapies in metastatic melanoma.","authors":"Daniel Y Wang,&nbsp;Douglas B Johnson","doi":"10.2217/mmt-2017-0005","DOIUrl":"https://doi.org/10.2217/mmt-2017-0005","url":null,"abstract":"","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"4 2","pages":"71-74"},"PeriodicalIF":3.6,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10752702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书